A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1473-IMIQ Study.

Trial Profile

A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1473-IMIQ Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2012

At a glance

  • Drugs Imiquimod (Primary)
  • Indications Actinic keratosis; Skin cancer
  • Focus Therapeutic Use
  • Sponsors 3M Pharmaceuticals; Graceway Pharmaceuticals
  • Most Recent Events

    • 31 Jan 2012 New trial record
    • 16 Feb 2007 Last checked against ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top